A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-28

Study Completion Date

2021-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Maintenance treatment can extend patient survival and improve patient quality of life. Bevacizumab alone or capecitabine combined with bevacizumab as a maintenance treatment have been widely used in clinical practice. In contrast, there are little datas of cetuximab as a maintenance treatment. The purpose of this study is to evaluate efficacy and safety of Raltitrexed plus Cetuximab as the maintenance treatment, and to provide a new choice for RAS wild-type colorectal cancer patients after advanced first-line chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer

NCT04262635

Colorectal Cancer

UNKNOWN PHASE3

A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer

NCT02717923

Colorectal Neoplasms

UNKNOWN PHASE2

Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis

NCT03031444

Colorectal Cancer Stage IV Metastasis

COMPLETED PHASE2/PHASE3

Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer

NCT05468177

Colonic Neoplasms

UNKNOWN PHASE2

Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker

NCT02043821

Metastatic Colorectal Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Maintenance treatment can prevent the toxicity and give patients a relative buffer period to alleviate the impact of follow-up treatment on the body without reducing efficacy. Bevacizumab alone or capecitabine combined with bevacizumab as a maintenance treatment have been widely used in clinical practice. There are little datas of cetuximab as a maintenance treatment ,some studies show that Cetuximab is effective in maintenance treatment, and some studies have reported adverse effects of Capecitabine combined with Cetuximab.So it is worthwhile to explore more suitable maintenance treatment options. Raltitrexed, a TS enzyme inhibitor, is an effective chemotherapy drug for colorectal cancer. We plan to evaluate efficacy and safety of Raltitrexed plus Cetuximab in maintenance treatment. Maybe we can provide a new choice for RAS wild-type colorectal cancer patients after advanced first-line chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Raltitrexed Plus Cetuximab

Group Type EXPERIMENTAL

Raltitrexed

Intervention Type DRUG

Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.

Cetuximab

Intervention Type DRUG

Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Raltitrexed

Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.

Intervention Type DRUG

Cetuximab

Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-75 years old, no gender restriction;
* RAS wild-type
* Unresectable metastatic colorectal cancer confirmed by histopathology and / or cytology;
* Disease stable or improved while on first-line use of FOLFOX/FOLFIRI with cetuximab for 4-6 months;
* At least one measurable objective tumor lesion by spiral CT scan，the longest diameter measured ≧ 10 mm，or by conventional CT scan，the diameter measured ≧ 20 mm.
* Eastern Cooperative Oncology Group (ECOG) general status score is 0-2;
* Life expectancy of at least 3 months;
* Blood routine, liver and kidney function within the 7 days before screening meet the following criteria: Absolute neutrophil count ≥ 1.5x10\^9 / L; hemoglobin ≥ 9.0 g / dl; platelet count ≥ 80 x10\^9 / L; total bilirubin ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase ≤ 2.5 x ULN (≤5 x ULN in patients with liver metastases); ≤3 x ULN in patients with liver metastases (≤5 x ULN in patients with liver metastases); serum creatinine ≤1.5 x ULN;
* Agree to sign informed consent.

Exclusion Criteria

* BRAF mutant
* Symptomatic brain or meningeal metastases (unless patients receive treatment\> 6 months, imaging results are negative within 4 weeks before joining the study, and tumor-related clinical symptoms are stable before joining the study);
* Previous malignant disease within five years, with the exception of the cured primary cervical cancer or basal cell carcinoma of the skin;
* Chronic intestinal disease, infectious intestinal disease, intestinal obstruction, active clinical severe infection and other diseases;
* With ascites
* Substance abuse and medical, psychological or social conditions that may interfere with the participation of patients in the study or influence the evaluation of the results of the study;
* Unsuitable for the study or other chemotherapy determined by investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No